文献速递关节外科

初次全膝关节置换术后血栓栓塞与出血并发症:丹麦全国队列研究

Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
PubMed 文献 · Bone Joint J · 2021-01-01

该研究利用丹麦全国登记数据,纳入2013至2018年间接受初次全膝关节置换术并接受血栓预防治疗的患者,比较达肝素或达比加群与利伐沙班在90天内静脉血栓栓塞、大出血和全因死亡风险上的差异。结果显示,与利伐沙班相比,达肝素和达比加群与静脉血栓栓塞风险降低相关,而大出血和全因死亡无显著差异。

要点

  • 达肝素或达比加群相比利伐沙班与90天VTE风险降低相关。
  • 大出血和全因死亡风险在各治疗组间无显著差异。
  • 倾向评分匹配分析与多变量分析结果一致。

核心结论

  • 与利伐沙班相比,达肝素或达比加群治疗与初次全膝关节置换术后90天静脉血栓栓塞风险降低相关。

研究设计与样本

  • 共纳入27,736例患者,其中利伐沙班组18,846例,达肝素组5,767例,达比加群组1,443例,亭扎肝素组1,372例,依诺肝素组308例。
  • 采用Cox回归模型计算风险比(HR)及95%置信区间(CI),并以利伐沙班为参照进行多变量分析和倾向评分匹配分析。

主要发现

  • 在多变量调整分析中,与利伐沙班相比,达肝素组VTE风险HR为0.68(95% CI 0.49至0.92),达比加群组HR为0.31(95% CI 0.13至0.70)。
  • 大出血和全因死亡风险在各治疗组间无统计学显著差异。
  • 倾向评分匹配分析结果与多变量分析相似。

关键数值与推荐

  • 主要结局为术后90天内静脉血栓栓塞、大出血和全因死亡风险。
  • 达肝素相比利伐沙班VTE风险HR 0.68(95% CI 0.49至0.92)。
  • 达比加群相比利伐沙班VTE风险HR 0.31(95% CI 0.13至0.70)。

临床怎么用

  • 对于接受初次全膝关节置换术的患者,选择达肝素或达比加群进行血栓预防可能较利伐沙班降低静脉血栓栓塞风险。
  • 临床决策时需综合考虑静脉血栓栓塞预防效果与大出血风险,尽管本研究未发现大出血风险显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study is to compare the effectiveness and safety of thromboprophylactic treatments in patients undergoing primary total knee arthroplasty (TKA). METHODS: Using nationwide medical registries, we identified patients with a primary TKA performed in Denmark between 1 January 2013 and 31 December 2018 who received thromboprophylactic treatment. We examined the 90-day risk of venous thromboembolism (VTE), major bleeding, and all-cause mortality following surgery. We used a Cox regression model to compute hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome, pairwise comparing treatment with dalteparin or dabigatran with rivaroxaban as the reference. The HRs were both computed using a multivariable and a propensity score matched analysis. RESULTS: We identified 27,736 primary TKA patients who received thromboprophylactic treatment (rivaroxaban (n = 18,846); dalteparin (n = 5,767); dabigatran (n = 1,443); tinzaparin (n = 1,372); and enoxaparin (n = 308)). In the adjusted multivariable analysis and compared with rivaroxaban, treatment with dalteparin (HR 0.68 (95% CI 0.49 to 0.92)) or dabigatran (HR 0.31 (95% CI 0.13 to 0.70)) was associated with a decreased risk of VTE. No statistically significant differences were observed for major bleeding or all-cause mortality. The propensity score matched analysis yielded similar results. CONCLUSION: Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban. Cite this article: Bone Joint J 2021;103-B(10):1571-1577.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Schelde AB, Petersen J, Jensen TB, et al. Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study. Bone Joint J. 2021. PMID: 34587805. doi:10.1302/0301-620X.103B10.BJJ-2021-0023.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。